IL17A and thymoma: Interestingly, anti-IL-17 and anti-IL-22 antibodies were also found in CMC patients with thymomas with aberrant expression of AIRE, suggesting that dysregulation of central tolerance drives the generation of anti-cytokine antibodies and subsequent CMC development [60].